Balyasny Asset Management
FBLG icon

Balyasny Asset Management’s FibroBiologics FBLG Stock Holding History

Balyasny Asset Management’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-712
Closed -$154K – 3196
2024
Q1 		$154K Buy
+712
New +$171K ﹤0.01% 2454

Other funds holding FBLG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TW
Transform Wealth Greenwood Village, Colorado $1.65B AUM 19.1% 1-Year Est. Return
OAS
Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $537M AUM 12.29% 1-Year Est. Return
AIFAIM
American Institute for Advanced Investment Management Scottsdale, Arizona $173M AUM 25.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Balyasny Asset Management's FBLG Position: Q2 2024 in Review

Balyasny Asset Management sold out of FibroBiologics (FBLG) in Q2 2024, closing a stake of 712 shares — an estimated $154K sold.

Balyasny Asset Management first reported a position in FBLG in Q1 2024 and held it in 1 quarter. The position peaked at $154K in Q1 2024. 50 funds tracked by Wall St. Rank hold FBLG as of Q2 2024.

  • Balyasny Asset Management reported no remaining FibroBiologics position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 712 FibroBiologics shares in Q2 2024, an estimated $154K.
  • Balyasny Asset Management first reported a position in FibroBiologics in Q1 2024 and held it in 1 quarter.
  • Balyasny Asset Management's FibroBiologics position peaked at $154K in Q1 2024.
  • 50 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.